Simris Alg AB (FRA:5LU) Net-Net Working Capital: €-0.01 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:5LU Simris Alg AB FRA:5LU
28 GF Score
Price €0.01
! 6 Warning Signs
View Full Analysis

What is Simris Alg AB Net-Net Working Capital?

Simris Alg AB FRA:5LU 28 Net-Net Working Capital is €-0.01 as of Mar. 2026. GuruFocus rates FRA:5LU with a GF Score™ of 28/100. The stock has 6 warning signs investors should review. Among 858 Biotechnology companies, Simris Alg AB ranks worse than 116550% on this metric.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Simris Alg AB's Net-Net Working Capital for the quarter that ended in Mar. 2026 was €-0.01.

The industry rank for Simris Alg AB's Net-Net Working Capital or its related term are showing as below:

FRA:5LU's Price-to-Net-Net-Working-Capital is not ranked *
in the Biotechnology industry.
Industry Median: 5.075
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Simris Alg AB  (FRA:5LU) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Simris Alg AB Net-Net Working Capital Related Terms


Simris Alg AB Net-Net Working Capital Historical Data

* Premium members only.

The historical data trend for Simris Alg AB's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Simris Alg AB Net-Net Working Capital Chart

Simris Alg AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.08 -0.04 -0.02 -0.02

Simris Alg AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.03 -0.02 -0.02 -0.02 -0.01

FRA:5LU vs VRTX, REGN, RVMD: Net-Net Working Capital Comparison

For the Biotechnology subindustry, Simris Alg AB's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Simris Alg AB Price-to-Net-Net-Working-Capital vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Simris Alg AB's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Simris Alg AB's Price-to-Net-Net-Working-Capital falls into.


FRA:5LU
28GF Score
Simris Alg AB FRA:5LU
Net-Net Working Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Simris Alg AB Net-Net Working Capital Calculation

Simris Alg AB's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2025 is calculated as

Net-Net Working Capital(A: Dec. 2025 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.135+0.75 * 0.007+0.5 * 0.099-13.678
-0-0)/842.105
=-0.02

Simris Alg AB's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2026 is calculated as

Net-Net Working Capital(Q: Mar. 2026 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(0.999+0.75 * 0+0.5 * 0.101-12.717
-0-0)/1349.793
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.

What does a Net-Net Working Capital of €-0.01 mean?
Simris Alg AB (FRA:5LU) has a Net-Net Working Capital of €-0.01 as of Mar. 2026. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Simris Alg AB According to the industry distribution chart, Simris Alg AB ranks #999999 out of 858 companies in the Biotechnology industry.
Is Simris Alg AB's Net-Net Working Capital too high?
Simris Alg AB's current Net-Net Working Capital is €-0.01. Based on the distribution chart, Simris Alg AB ranks #999999 out of 858 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Simris Alg AB has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Simris Alg AB's Net-Net Working Capital compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Simris Alg AB ranks #999999 out of 858 companies for Net-Net Working Capital. This places Simris Alg AB in the lower half of its industry. The industry median Net-Net Working Capital is 5.08. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net-Net Working Capital for a Biotechnology company?
The median Net-Net Working Capital among Biotechnology companies is 5.08, based on 858 companies in the industry. Companies in the top quartile (top 25%) have a Net-Net Working Capital significantly above this median, while those in the bottom quartile fall well below. However, Net-Net Working Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net-Net Working Capital mean?
A high Net-Net Working Capital can signal that a stock is expensive relative to its fundamentals. Ben Graham defined net-net working capital as the per-share sum of cash, 75% of receivables and 50% of inventory less total liabilities. View historical data on Simris Alg AB For the Biotechnology industry, the median Net-Net Working Capital is 5.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Simris Alg AB's current Net-Net Working Capital is €-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Simris Alg AB stock overvalued right now?
Simris Alg AB (FRA:5LU) has a current Net-Net Working Capital of €-0.01. The current Net-Net Working Capital is €-0.01. Simris Alg AB's overall GF Score™ is 28/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net-Net Working Capital calculated?
Net-Net Working Capital is calculated from a company's financial statements. For Simris Alg AB (FRA:5LU), the current Net-Net Working Capital is €-0.01 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Simris Alg AB Business Description

Other Exchanges SIMRIS B:Sweden
Address Herrestadsvagen 24A, Hammenhog, SWE, 276 50
Simris Alg AB is a biotechnology company, engaged in research, development and production of bioactive substances from microalgae, for nutraceutical, cosmeceutical and pharmaceutical applications. The company's technology provides access to bioactive substances with novel functions, while replacing unsustainable raw materials from endangered marine species and ecosystems. Its first commercialised range is a series of omega-3 health supplements marketed under the company's own brand.
28GF Score

Get the complete analysis for FRA:5LU

Net-Net Working Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.01
Price